nilla, Author at European Medical Journal - Page 12 of 20

Reverse mentoring: a how-to guide

Reverse mentoring challenges the status quo and flips traditional learning dynamics on their axis. This how-to guide deconstructs what must be considered when building a reverse mentoring scheme in pharma.

Overcoming decentralised clinical trial obstacles

How can emergency measures be translated into permanent solutions to increase the power and number of these trials?

The physics of pharmacovigilance

A highly-effective pharmacovigilance function is a rising value differentiator for pharmaceutical companies. Read to find out more about the challenges.

Killing projects, drug discovery and career progression

This week, the GOLD team is joined by Eric Bouilloux, Chief Development Officer, Istesso, to talk about immunometabolism and pharma predictions.

The progress and pain points of patient centricity

The pharmaceutical industry views itself as increasingly patient centric, but do two patient advocates agree? In this roundtable discussion, they consider what the industry is doing well, and their views on how it could improve further

Gamification: retaining a human touch and enhancing culture

In this episode, GOLD is joined by Natalie Yeadon, Co-founder and CEO of Impetus Digital to talk all things gamification in pharma.

Getting to grips with customer experience

Join Isabel and Jade in kicking off Season 5 of the GOLD podcast with an interview with Philippe Kirby, Global Head of Channel Engagement and Execution, MSD.

Pharma in South Africa, access, pricing and reimbursement

In this episode, GOLD is joined by two international experts in market access, talking about pricing, reimbursement and more in South Africa and Europe.

Learnings from the Next Pharma Summit

In this bonus episode, Helena offers her reflections on the Next Pharma Summit, and Isabel catches up with the event founder Dario Safaric.

Communication, data in R&D and leadership

In this episode, Helena and Marc are joined by Amgen’s Emma Booth to discuss all things R&D, plus medical affairs communication and more.